1. Home
  2. NVCT vs JRVR Comparison

NVCT vs JRVR Comparison

Compare NVCT & JRVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCT
  • JRVR
  • Stock Information
  • Founded
  • NVCT 2020
  • JRVR 2002
  • Country
  • NVCT United States
  • JRVR Bermuda
  • Employees
  • NVCT N/A
  • JRVR N/A
  • Industry
  • NVCT Medicinal Chemicals and Botanical Products
  • JRVR Property-Casualty Insurers
  • Sector
  • NVCT Health Care
  • JRVR Finance
  • Exchange
  • NVCT Nasdaq
  • JRVR Nasdaq
  • Market Cap
  • NVCT 170.3M
  • JRVR 181.2M
  • IPO Year
  • NVCT 2022
  • JRVR 2005
  • Fundamental
  • Price
  • NVCT $9.35
  • JRVR $4.16
  • Analyst Decision
  • NVCT Strong Buy
  • JRVR Buy
  • Analyst Count
  • NVCT 2
  • JRVR 4
  • Target Price
  • NVCT $15.00
  • JRVR $6.06
  • AVG Volume (30 Days)
  • NVCT 127.6K
  • JRVR 325.2K
  • Earning Date
  • NVCT 05-06-2025
  • JRVR 03-03-2025
  • Dividend Yield
  • NVCT N/A
  • JRVR 0.96%
  • EPS Growth
  • NVCT N/A
  • JRVR N/A
  • EPS
  • NVCT N/A
  • JRVR N/A
  • Revenue
  • NVCT N/A
  • JRVR $707,626,000.00
  • Revenue This Year
  • NVCT N/A
  • JRVR $13.51
  • Revenue Next Year
  • NVCT N/A
  • JRVR $5.87
  • P/E Ratio
  • NVCT N/A
  • JRVR N/A
  • Revenue Growth
  • NVCT N/A
  • JRVR N/A
  • 52 Week Low
  • NVCT $4.44
  • JRVR $3.00
  • 52 Week High
  • NVCT $11.80
  • JRVR $9.56
  • Technical
  • Relative Strength Index (RSI)
  • NVCT 56.56
  • JRVR 46.90
  • Support Level
  • NVCT $8.45
  • JRVR $4.13
  • Resistance Level
  • NVCT $10.71
  • JRVR $4.38
  • Average True Range (ATR)
  • NVCT 1.01
  • JRVR 0.15
  • MACD
  • NVCT 0.03
  • JRVR 0.05
  • Stochastic Oscillator
  • NVCT 57.01
  • JRVR 57.69

About NVCT Nuvectis Pharma Inc.

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.

About JRVR James River Group Holdings Ltd.

James River Group Holdings Ltd owns and operates a group of specialty insurance and reinsurance companies. It reports business into three segments. The Excess and Surplus Lines segment, which is the key revenue driver, offers commercial excess and surplus lines liability and excess property insurance products; The Specialty Admitted Insurance segment focuses on niche classes within the standard insurance markets with a primary focus on fronting business, where it retains a minority share of the risk and seek to earn fee income by allowing other carriers and producers to use its licensure, ratings, expertise and infrastructure. and the Corporate and other segment consists of the management and treasury activities of holding companies, equity compensation for the group.

Share on Social Networks: